---
title: "Amicus Therapeutics Repays and Terminates 2023 Blackstone Credit Agreement Following Merger"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284245917.md"
description: "Amicus Therapeutics has fully repaid and terminated its loan agreement with Blackstone, originally dated October 2, 2023, in connection with its merger closing on April 27, 2026. The termination, which incurs no exit fees, simplifies the company's capital structure post-transaction. The agreement involved Blackstone Alternative Credit Advisors, Blackstone Life Sciences Advisors, and Wilmington Trust as the agent."
datetime: "2026-04-27T15:53:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284245917.md)
  - [en](https://longbridge.com/en/news/284245917.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284245917.md)
generator: "portal-rs"
---

# Amicus Therapeutics Repays and Terminates 2023 Blackstone Credit Agreement Following Merger

Amicus Therapeutics repaid in full all outstanding amounts and terminated all commitments under its Oct. 2, 2023 loan agreement in connection with the merger closing on Apr. 27, 2026. The facility, arranged with Blackstone Alternative Credit Advisors, Blackstone Life Sciences Advisors and certain lenders with Wilmington Trust as agent, was fully discharged and the related guarantees and liens were released. The early termination carries no disclosed exit fees and is expected to simplify the company's capital structure post-transaction.

**Agreement details:**

-   **Agreement terminated**: Secured loan agreement (Amicus Credit Agreement)
-   **Counterparty**: Blackstone Alternative Credit Advisors; Blackstone Life Sciences Advisors; Wilmington Trust (agent); certain lenders
-   **Original agreement date**: Oct 02 2023
-   **Termination date**: Apr 27 2026
-   **Termination type**: Early
-   **Exit fees / payments**: None
-   **Reason**: Repayment in full upon merger closing

Original SEC Filing: AMICUS THERAPEUTICS, INC. \[ FOLD \] - 8-K - Apr. 27, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [FOLD.US](https://longbridge.com/en/quote/FOLD.US.md)
- [BX.US](https://longbridge.com/en/quote/BX.US.md)

## Related News & Research

- [National Healthcare Properties director Albert M. Campbell III files initial beneficial ownership statement](https://longbridge.com/en/news/296401234.md)
- [Adaptive Biotechnologies Director Sold Shares Worth Over $748K](https://longbridge.com/en/news/296540760.md)
- [Adaptive Biotechnologies Director Sold Shares Worth Over $3.1M](https://longbridge.com/en/news/296413222.md)
- [Mesa Laboratories Director Sold Shares Worth Over $800K](https://longbridge.com/en/news/296130026.md)
- [Most of Gen Z is now afraid AI will steal their jobs.](https://longbridge.com/en/news/296492576.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**